Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has ...

However, the increase in ABBV stock has been far from consistent. Returns for the stock were 32% in 2021, 24% in 2022, and 0% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19 ...